Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 240 (2), 221-4

The Anti-Obesity Agent Orlistat Is Associated to Increase in Colonic Preneoplastic Markers in Rats Treated With a Chemical Carcinogen

Affiliations

The Anti-Obesity Agent Orlistat Is Associated to Increase in Colonic Preneoplastic Markers in Rats Treated With a Chemical Carcinogen

Sérgio Britto Garcia et al. Cancer Lett.

Abstract

Orlistat is an anti-obesity agent that increases the fecal fat excretion, which promotes colon carcinogenesis. Therefore, the present study was designed to verify the effects of Orlistat on the formation of rat colonic aberrant crypt foci (ACF) and cell proliferation evaluated by the PCNA method. Male Wistar rats received either a standard diet or a high fat diet (HFD), supplemented or not with Orlistat (200mg/kg chow) and two doses of the carcinogen dimethyl-hydrazine (25mg/Kg). After 30 days, Orlistat was associated to a significant increase in the number of colonic ACFs and cell proliferation in DMH-treated animals, independently of the HFD.

Similar articles

See all similar articles

Cited by 13 PubMed Central articles

See all "Cited by" articles

Publication types

MeSH terms

Feedback